The Latest Analyst Ratings for Karuna Therapeutics
Portfolio Pulse from Benzinga Insights
Karuna Therapeutics (NASDAQ:KRTX) has received positive analyst ratings in the last quarter, with 10 bullish ratings and an average price target of $278.4, indicating potential upside from the current price of $209.58. The average price target has increased by 6.34% from the previous average of $261.80.
July 13, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karuna Therapeutics has received positive analyst ratings, indicating potential upside.
Analyst ratings are a key indicator of a stock's potential performance. The positive ratings and increased price target for Karuna Therapeutics suggest that analysts are optimistic about the stock's future performance, which could drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100